{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T16:34:41Z","timestamp":1759336481415,"version":"3.37.3"},"reference-count":11,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2019,12,19]],"date-time":"2019-12-19T00:00:00Z","timestamp":1576713600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2019,12,19]],"date-time":"2019-12-19T00:00:00Z","timestamp":1576713600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Invest New Drugs"],"published-print":{"date-parts":[[2020,6]]},"DOI":"10.1007\/s10637-019-00887-0","type":"journal-article","created":{"date-parts":[[2019,12,19]],"date-time":"2019-12-19T23:02:37Z","timestamp":1576796557000},"page":"874-884","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Evaluation of the potential effect of dacomitinib, an EGFR tyrosine kinase inhibitor, on ECG parameters in patients with advanced non-small cell lung cancer"],"prefix":"10.1007","volume":"38","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8915-1152","authenticated-orcid":false,"given":"Weiwei","family":"Tan","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nagdeep","family":"Giri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Susan","family":"Quinn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Keith","family":"Wilner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kourosh","family":"Parivar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2019,12,19]]},"reference":[{"issue":"24","key":"887_CR1","doi-asserted-by":"publisher","first-page":"11924","DOI":"10.1158\/0008-5472.CAN-07-1885","volume":"67","author":"JA Engelman","year":"2007","unstructured":"Engelman JA, Zejnullahu K, Gale CM, Lifshits E, Gonzales AJ, Shimamura T, Zhao F, Vincent PW, Naumov GN, Bradner JE, Althaus IW, Gandhi L, Shapiro GI, Nelson JM, Heymach JV, Meyerson M, Wong KK, Janne PA (2007) PF00299804, an irreversible pan-ERBB inhibitor, is effective in lung cancer models with EGFR and ERBB2 mutations that are resistant to gefitinib. Cancer Res 67(24):11924\u201311932. https:\/\/doi.org\/10.1158\/0008-5472.CAN-07-1885","journal-title":"Cancer Res"},{"issue":"11","key":"887_CR2","doi-asserted-by":"publisher","first-page":"1454","DOI":"10.1016\/S1470-2045(17)30608-3","volume":"18","author":"YL Wu","year":"2017","unstructured":"Wu YL, Cheng Y, Zhou X, Lee KH, Nakagawa K, Niho S, Tsuji F, Linke R, Rosell R, Corral J, Migliorino MR, Pluzanski A, Sbar EI, Wang T, White JL, Nadanaciva S, Sandin R, Mok TS (2017) Dacomitinib versus gefitinib as first-line treatment for patients with EGFR-mutation-positive non-small-cell lung cancer (ARCHER 1050): a randomised, open-label, phase 3 trial. Lancet Oncol 18(11):1454\u20131466. https:\/\/doi.org\/10.1016\/S1470-2045(17)30608-3","journal-title":"Lancet Oncol"},{"issue":"22","key":"887_CR3","doi-asserted-by":"publisher","first-page":"2244","DOI":"10.1200\/JCO.2018.78.7994","volume":"36","author":"TS Mok","year":"2018","unstructured":"Mok TS, Cheng Y, Zhou X, Lee KH, Nakagawa K, Niho S, Lee M, Linke R, Rosell R, Corral J, Migliorino MR, Pluzanski A, Sbar EI, Wang T, White JL, Wu YL (2018) Improvement in overall survival in a randomized study that compared dacomitinib with gefitinib in patients with advanced non-small-cell lung cancer and EGFR-activating mutations. J Clin Oncol 36(22):2244\u20132250. https:\/\/doi.org\/10.1200\/JCO.2018.78.7994","journal-title":"J Clin Oncol"},{"key":"887_CR4","unstructured":"VIZIMPRO\u00ae (dacomitinib) tablets: US prescribing information (2018) Pfizer, Inc.; 2018"},{"issue":"6","key":"887_CR5","doi-asserted-by":"publisher","first-page":"1011","DOI":"10.1038\/bjc.2015.82","volume":"112","author":"JS Kloth","year":"2015","unstructured":"Kloth JS, Pagani A, Verboom MC, Malovini A, Napolitano C, Kruit WH, Sleijfer S, Steeghs N, Zambelli A, Mathijssen RH (2015) Incidence and relevance of QTc-interval prolongation caused by tyrosine kinase inhibitors. Br J Cancer 112(6):1011\u20131016. https:\/\/doi.org\/10.1038\/bjc.2015.82","journal-title":"Br J Cancer"},{"issue":"4","key":"887_CR6","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1177\/009286150503900407","volume":"39","author":"PT Sager","year":"2005","unstructured":"Sager PT, Nebout T, Darpo B (2005) ICH E14: a new regulatory guidance on the clinical evaluation of QT\/QTc internal prolongation and proarrhythmic potential for non-antiarrhythmic drugs. Drug Inf J 39(4):387\u2013394. https:\/\/doi.org\/10.1177\/009286150503900407","journal-title":"Drug Inf J"},{"issue":"1","key":"887_CR7","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1111\/anec.12128","volume":"19","author":"B Darpo","year":"2014","unstructured":"Darpo B, Sarapa N, Garnett C, Benson C, Dota C, Ferber G, Jarugula V, Johannesen L, Keirns J, Krudys K, Ortemann-Renon C, Riley S, Rogers-Subramaniam D, Stockbridge N (2014) The IQ-CSRC prospective clinical phase 1 study: \u201ccan early QT assessment using exposure response analysis replace the thorough QT study?\u201d. Ann Noninvasive Electrocardiol 19(1):70\u201381. https:\/\/doi.org\/10.1111\/anec.12128","journal-title":"Ann Noninvasive Electrocardiol"},{"key":"887_CR8","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1016\/j.lungcan.2017.08.017","volume":"112","author":"HA Yu","year":"2017","unstructured":"Yu HA, Ahn MJ, Cho BC, Gerber DE, Natale RB, Socinski MA, Giri N, Quinn S, Sbar E, Zhang H, Giaccone G (2017) Phase 2 study of intermittent pulse dacomitinib in patients with advanced non-small cell lung cancers. Lung Cancer 112:195\u2013199. https:\/\/doi.org\/10.1016\/j.lungcan.2017.08.017","journal-title":"Lung Cancer"},{"issue":"13","key":"887_CR9","doi-asserted-by":"publisher","first-page":"1433","DOI":"10.1016\/S1470-2045(14)70461-9","volume":"15","author":"PA Janne","year":"2014","unstructured":"Janne PA, Ou SH, Kim DW, Oxnard GR, Martins R, Kris MG, Dunphy F, Nishio M, O'Connell J, Paweletz C, Taylor I, Zhang H, Goldberg Z, Mok T (2014) Dacomitinib as first-line treatment in patients with clinically or molecularly selected advanced non-small-cell lung cancer: a multicentre, open-label, phase 2 trial. Lancet Oncol 15(13):1433\u20131441. https:\/\/doi.org\/10.1016\/S1470-2045(14)70461-9","journal-title":"Lancet Oncol"},{"issue":"2","key":"887_CR10","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1002\/jcph.588","volume":"56","author":"A Ruiz-Garcia","year":"2016","unstructured":"Ruiz-Garcia A, Masters JC, Mendes da Costa L, LaBadie RR, Liang Y, Ni G, Ellery CA, Boutros T, Goldberg Z, Bello CL (2016) Effect of food or proton pump inhibitor treatment on the bioavailability of dacomitinib in healthy volunteers. J Clin Pharmacol 56(2):223\u2013230. https:\/\/doi.org\/10.1002\/jcph.588","journal-title":"J Clin Pharmacol"},{"issue":"5","key":"887_CR11","doi-asserted-by":"publisher","first-page":"1131","DOI":"10.1158\/1078-0432.CCR-10-1220","volume":"17","author":"PA Janne","year":"2011","unstructured":"Janne PA, Boss DS, Camidge DR, Britten CD, Engelman JA, Garon EB, Guo F, Wong S, Liang J, Letrent S, Millham R, Taylor I, Eckhardt SG, Schellens JH (2011) Phase I dose-escalation study of the pan-HER inhibitor, PF299804, in patients with advanced malignant solid tumors. Clin Cancer Res 17(5):1131\u20131139. https:\/\/doi.org\/10.1158\/1078-0432.CCR-10-1220","journal-title":"Clin Cancer Res"}],"container-title":["Investigational New Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10637-019-00887-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10637-019-00887-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10637-019-00887-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,3,11]],"date-time":"2023-03-11T04:38:24Z","timestamp":1678509504000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10637-019-00887-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,12,19]]},"references-count":11,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2020,6]]}},"alternative-id":["887"],"URL":"https:\/\/doi.org\/10.1007\/s10637-019-00887-0","relation":{},"ISSN":["0167-6997","1573-0646"],"issn-type":[{"type":"print","value":"0167-6997"},{"type":"electronic","value":"1573-0646"}],"subject":[],"published":{"date-parts":[[2019,12,19]]},"assertion":[{"value":"2 December 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 December 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 December 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"WT, KW and KP are employees of and own stock in Pfizer Inc. NG and SQ were employees of Pfizer Inc. during the analysis of the manuscript.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and\/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Informed consent was obtained from all individual participants included in the study.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}